Premium
Indium‐111‐labeled anti‐egfr‐425 scintigraphy in the detection of malignant gliomas
Author(s) -
Dadparvar Simin,
Krishna Lalitha,
Miyamoto Curtis,
Brady Luther W.,
Brown Steven J.,
Bender Hans,
Slizofski Walter J.,
Eshleman Jeffrey,
Chevres Anita,
Woo David V.
Publication year - 1994
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19940201)73:3+<884::aid-cncr2820731320>3.0.co;2-u
Subject(s) - medicine , radioimmunotherapy , epidermal growth factor receptor , nuclear medicine , glioma , monoclonal antibody , biopsy , scintigraphy , pathology , antibody , cancer , cancer research , immunology
Background . The monoclonal antibody anti‐epidermal growth factor receptor (EGFr)antibody‐425, against the epidermal growth factor receptor, has the potential to bind specifically to gliomas and not normal brain tissue. 1–3 A prospective study was conducted (1986–1988) to evaluate the use of Indium‐111 ( 111 In)‐labeled anti‐EGFr‐425 in the localization of gliomas before radioimmunotherapy with Iodine‐125 ( 125 I)‐labeled anti‐EGFr‐425. Methods . Twenty‐eight patients with intracranial neoplasms were injected intravenously with an average dose of 2.2 mCi 111 In‐labeled anti‐EGFr‐425. Planar and single‐photon emission computed tomography scans were performed after 48 and 72 hours. Control studies also were performed in two cases with 111 In‐labeled Co 17‐1A (a, *I antibody to colorectal cancer) and in one case with unlabeled 111 In chloride. Results . The immunoscintigraphic findings were generally in good agreement with computerized tomographic findings. The definitive diagnosis was established by biopsy findings: 23 gliomas (1 Grade I, 5 Grade II, 6 Grade III, and 11 Grade IV), 1 meningioma, and 4 metastatic lesions. The localization of gliomas with 111 In‐labeled anti‐EGF‐425 had a sensitivity of 0.96, a specificity of 0.60 and an accuracy of 0.90. Conclusion . Immunoscintigraphy with 111 ‐In labeled anti‐EGFr‐425 can be useful in the management of malignant gliomas, especially before radioimmunotherapy with 125 I‐labeled anti‐EGFr‐425. Cancer 1994; 73:884–9.